<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr><td>1</td><td>Name of Company</td><td>Mangalam Drugs & Organics Ltd</td></tr> <tr><td>2</td><td>CIN NO.</td><td>L24230MH1972PLC116413</td></tr> <tr><td>3</td> <td>Outstanding borrowing of company as on 31st March / 31st December, as ....

Mangalam Drugs and Organics Limited Regd. Office : Rupam Building, 3rd Floo23r9 ,P, 0'Mallg Road, NearG . P. 0. Mum-b 40a0 0i01 @ QI—Z—ZV—GZG—I(—)Z—OU/— 6—30—0/—87—87 @P& 79T12- 22/20-266216199009900 «e CCIINN : LL2244223300MMHH1199772 PLC116413 REF: MDOL/CS-SE/2026-27/0032 Date: 28th September, 2026 The Manager (Listing/Compliance), To, Corporate Relationship The Manager (Listing/(:ompliance), Department, BSE Limited, National Stock Exchange of India Ltd., DP ah li ar lo z Ste J eee te ,j e Me ub mh bo ay T -o 4w 0e 0rs 0, BE ax nc dh ra an g Ke u rla P Cl oa mza p, ex,C M-1 u, baiBl -oc 4k 0051G, BSE Scrip Code 532637 Scrip Name: MAN GALAM bd yat b Iej se d sc ut 2: a n6 c eN N o oon v fa e Dp mp ebl bei tc r a S,b e i c2l ui 0 r i1 t8 i ea sf s ba ymS EB LeI an rd gC e ei dr Ec nu f tl r ia tr o 0 t ,. ime S tEB oI time regaS r/ dC iI ngR / FP u/ n2 d Raisin4 g (ISIN No. lNE584F01014) Dear Sir/Madam, Dm3dtS io1eiE sdm sc cB ie l t l, fa I M oir/ w a sceiH ur a tr rO tcahe eihn/ f o,drD ie n ne Dr s2 cge sH 0a o pn S a2r n ec n/ d f 6 ce d C i i t f arI o is em R ef t n/ p do u t ae P n h c fra/ d t o t Z t rmr hO a C meei1 ano s t8 tm fi s/ pn r oa g f1 a a tb m4 n mb ho a4 y eyv ed w e id eoi as a fs rst o u ,f n k ec ra ro da epn t o p sc r2 mt ae f o ii a6 vo dtlo if l i n d ci mN de in e eo ed g r.dv b c ue t ui H ln m n ess a db e nu t receb c hu irrj ee sr e , ,i L nac t fa ot 2 ti or t0 e hrg s e1 aee a p8 b s r pn ay C lea id o ils qd r ca upa r ac iog i bmS re r r leE e c eaeB n mu tn] tl ed et oa i n e rt tc td i ha iC e et ns oi f , ce fr r lgc wo ou fu oem id ml r l a i py it hr n n ai e ga g nm r s a ye te n o .hbt y en yo The details required as per Annexure A of the said circular are enclosed. You are requested to please consider the same and take on record. Thanking you, Yours faithfully FOR MANGALAM D 3 AND ORGANICS LIMITED COMPANY SECRETARY MM .s . S O.h w Ae 7t 4a P 8a 5t el Encl.: As Above, Factory : at Vapi (Gujarat) India ® contactus@mangalamdrugs.com @ http://www.ma ngalamdrugs.com Mangalam Drugs and Organics Limited MANGALAM Regd. Office : ®Ru 9pa 1m - Bu 2il 2di :ng 6, 23r 6d 1F 6lo 36o 0r 20, /02 3 809 7 8/P. 7 D @' M 9el 1l -o 2 2R -o 6a 2d 6, 1 N 9e 0a 9r 0 G «. CP, I NO . : M Lu 24m 2b 3a 0i M - H 4 10 90 7 20 P0 L1 C 116413 — WH_ o-— GM e | Accred d Annexure-A Initial disclosure to be made by an entity identified as a Large Corporate [S.No | Particulars Details 01 Name of the company Mangalam Drugs and Organics Limited 02 CIN 03 Outstanding borrowing of company as on 315t | 7L 42 94 .2 73 60 lM aH k1 hs9 72PLC116413 March, as applicable (in Rs. crore) 04 Highest credit rating during the previous FY | CRISIL-D along with name oft he CRA 05 bN ea m pe do ,f s it no c ck se ex c oh fa n sg hoe ti fn w llh i ic nh tt hh ee f ri en qe s ih ra el dl | Not Applicable borrowing under the framework t 1W h 3e e t Cc Aho pan rp if lti er 2rm 0 2Xt I 2h I .a t o fw e SE a Br Ie O n po ert a a t iL oa nr ag le cC io rcr up lo ar ra dt ae t a es d p Ae ur g ut she t a 1p 0p ,l 2ic 0a 2b 1il i at ny d c fri ut re tr hi ea r g ui pv de an t u en dd oe nr CS & Compliance Email: cs@mangalamdrugs.com EC mh ai ie lf F ]in da an lc vi ia @l mO af nfi gc ae lr a mdrugs.com Date: 28t September, 2026 Place: Mumbai Factory : at Vapi (Gujarat) India @ contactus@mangalamdrugs.com @ http://www. nangalamdrugs.com